Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Tebotelimab · MGD013

Bispecific antibody · Immune activation, directed at Programmed cell death protein 1 (PDCD1) and Lymphocyte activation gene 3 protein (LAG3) · developed by MacroGenics

Phase 2/3 Most advanced trial (none active)
MGNX Developer
5 Registered trials

What is Tebotelimab?

Tebotelimab is a humanized, Fc-bearing antibody-like protein that binds both PD-1 and LAG-3, immune checkpoint molecules expressed on T cells. Dual blockade of these pathways is intended to enhance cytotoxic T-lymphocyte responses against tumor cells. It is being studied in advanced solid tumors, hematologic neoplasms, and several carcinomas including ovarian, lung, gastric, breast and biliary tract cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
MGD013
Drug type
Bispecific antibody
Targets
Programmed cell death protein 1 (PDCD1), Lymphocyte activation gene 3 protein (LAG3)
Mechanism
Immune activation, directed at Programmed cell death protein 1 (PDCD1) and Lymphocyte activation gene 3 protein (LAG3)
Pathways
T-cell activation, cytotoxic T-lymphocyte-mediated antitumor immune response
Therapy area
Oncology
Developer
MacroGenics (MGNX)
Also in trials of
ZLAB
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
L62556GPXB

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04082364 Phase 2/3 Gastric Cancer Completed MGNX
NCT04212221 Phase 1/2 Advanced Hepatocellular Carcinoma (HCC) Terminated ZLAB
NCT04653038 Phase 1 Unresectable, Recurrent or Metastatic Melanoma Terminated ZLAB
NCT04178460 Phase 1 Gastric Cancer Terminated ZLAB
NCT03219268 Phase 1 Advanced Solid Tumors Completed MGNX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorsBiliary Tract CarcinomaCervical CancerCholangiocarcinomaGastric CancerGastroesophageal Junction CancerHematologic NeoplasmsHER2-positive Advanced Solid TumorsHER2-positive Gastric CancerNon Small Cell Lung CancerOvarian CancerSmall-cell Lung CancerSquamous Cell Carcinoma of Head and NeckTNBC - Triple-Negative Breast Cancer

Other drugs acting on PDCD1 / LAG3

More from MacroGenics

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the MGNX page.

Follow MGNX, the company behind Tebotelimab

See MGNX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MGNX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.